| 1391 |
National Cancer Institute |
Html |
en |
Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of Wilms tumor. |
| wilms tumors | 0.503727 |
| wilms tumor | 0.905843 |
| Wilms tumor development | 0.5254 |
| Wilms tumor genetics | 0.517912 |
| Wilms Tumor Study-5 | 0.477443 |
| familial Wilms tumour | 0.446601 |
| favorable-histology wilms tumor | 0.511105 |
| stage II Wilms | 0.439212 |
| unilateral Wilms tumor | 0.553115 |
| Wilms tumor patients | 0.529584 |
| favorable histology Wilms | 0.460427 |
| bilateral Wilms patients | 0.460054 |
| Tumor Study Group | 0.595101 |
| contralateral Wilms tumor | 0.495745 |
| Wilms tumor-Aniridia syndrome | 0.439108 |
| preoperative wilms tumor | 0.505524 |
| bilateral wilms tumor | 0.635902 |
| stromal-type Wilms tumor | 0.516983 |
| Wilms tumor surveillance | 0.49553 |
| beckwith-wiedemann syndrome | 0.43423 |
| inoperable Wilms tumor | 0.526248 |
| Group/National Wilms Tumor | 0.47873 |
| Low-risk Wilms Tumor | 0.474612 |
| histology Wilms tumors | 0.433526 |
| Wilms Tumor Study | 0.723902 |
|
| Wilms tumor screening | 0.479856 |
| wilms tumor rupture | 0.501052 |
| et al. | 0.499553 |
| wilms tumor predisposition | 0.521351 |
| histology Wilms tumor | 0.504567 |
| Wilms tumours | 0.453209 |
| COG Wilms tumor | 0.518219 |
| SIOP Wilms Tumor | 0.504401 |
| Wilms tumour | 0.50015 |
| bilateral Wilms tumor. | 0.45063 |
| Pediatr Blood Cancer | 0.440629 |
| wilms tumor suppressor | 0.492641 |
| nonsyndromic Wilms tumor | 0.493832 |
| Metachronous bilateral Wilms | 0.434751 |
| National Wilms Tumor | 0.736085 |
| Med Genet | 0.447601 |
| Abstract | 0.531043 |
| Clin Oncol | 0.453706 |
| familial Wilms tumor. | 0.444435 |
| Wilms tumor locus | 0.521817 |
| Familial Wilms tumor | 0.495658 |
| non-WT1-syndromic Wilms tumor | 0.488494 |
| Wilms Tumor Study-3 | 0.478135 |
| Wilms tumor susceptibility | 0.497583 |
|
CLICK HERE |
| 1528 |
National Cancer Institute |
Html |
en |
Ovarian Low Malignant Potential Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors. |
| currently used treatment | 0.491433 |
| treatment | 0.80031 |
| abnormal cells | 0.591776 |
| cancer treatment | 0.491469 |
| ovaries | 0.553108 |
| abdomen | 0.566902 |
| body cavity | 0.495458 |
| NCI-supported cancer | 0.497228 |
| tissue | 0.516419 |
| cancer cells | 0.493195 |
| body | 0.515176 |
| Cancer Information Service | 0.489344 |
| low malignant potential | 0.507879 |
| PDQ cancer information | 0.620272 |
| clinical trial search | 0.566415 |
| uterus | 0.498028 |
| treatment clinical trials | 0.555055 |
| National Cancer Institute | 0.572253 |
| clinical trials | 0.964888 |
| tumor cells | 0.695966 |
| Treatment Options section | 0.484079 |
| cancer information summary | 0.567078 |
| clinical trial | 0.741404 |
| new treatment | 0.564234 |
|
| disease | 0.554973 |
| malignant potential tumor | 0.900634 |
| new treatments | 0.489278 |
| patients | 0.603036 |
| earlier clinical trials | 0.497766 |
| clinical trials database | 0.496798 |
| peritoneal cavity | 0.517264 |
| Potential Tumors Treatment | 0.491558 |
| treatment clinical trial | 0.511947 |
| PDQ Adult Treatment | 0.504736 |
| NCI PDQ cancer | 0.507801 |
| ovary | 0.536161 |
| cancer clinical trials | 0.578107 |
| tests | 0.498811 |
| stage | 0.7416 |
| malignant potential tumors | 0.621847 |
| fallopian tubes | 0.57444 |
| treatment options | 0.549139 |
| Treatment Editorial Board | 0.533517 |
| cancer information summaries | 0.487894 |
| comprehensive cancer information | 0.488381 |
| cancer | 0.721628 |
| standard treatment | 0.552748 |
|
CLICK HERE |
| 1712 |
National Cancer Institute |
Html |
en |
Antioxidants and Cancer Prevention |
A fact sheet about antioxidants, substances that may protect cells from the damage caused by unstable molecules known as free radicals. Free radical damage may lead to cancer. |
| Nutrition Intervention Trial | 0.501895 |
| esophageal cancer | 0.494202 |
| cancer prevention | 0.637226 |
| dietary antioxidant supplements | 0.628093 |
| Retinol Efficacy Trial | 0.539912 |
| antioxidants | 0.567107 |
| supplementation | 0.636543 |
| beta-carotene supplementation | 0.609246 |
| vitamin E supplementation | 0.519408 |
| randomized controlled trials | 0.504401 |
| trial | 0.573618 |
| daily supplementation | 0.567334 |
| lung cancer | 0.591669 |
| Alpha-Tocopherol/Beta-Carotene Cancer Prevention | 0.499391 |
| Health Study | 0.544001 |
| free radical damage | 0.506138 |
| beta-carotene supplements | 0.507967 |
| National Cancer Institute | 0.710208 |
| dietary antioxidants | 0.513132 |
| beta carotene | 0.496454 |
| cardiovascular disease | 0.651531 |
| Cancer Prevention Study | 0.537001 |
| Vitamin E Cancer | 0.510878 |
|
| free radicals | 0.842716 |
| exogenous antioxidants | 0.527581 |
| Cancer Prevention Trial | 0.559457 |
| alpha-tocopherol supplementation | 0.518828 |
| gastric cancer | 0.506898 |
| skin cancer incidence | 0.521176 |
| antioxidant vitamins | 0.499147 |
| cancer development | 0.495835 |
| total cancer incidence | 0.520828 |
| randomized controlled trial | 0.509347 |
| antioxidant supplementation | 0.554893 |
| antioxidant supplements | 0.754474 |
| prostate cancer | 0.575846 |
| effects | 0.540142 |
| all-cause mortality | 0.510888 |
| et al | 0.922404 |
| New England Journal | 0.537799 |
| cancer risk | 0.507337 |
| lung cancer incidence | 0.528817 |
| cancer | 0.94983 |
| incidence | 0.572134 |
| cancer incidence | 0.567041 |
| long-term beta-carotene supplementation | 0.539474 |
|
CLICK HERE |
| 1861 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de orofaringe (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de orofaringe. |
| Tabor MP | 0.407217 |
| enfermedad oral benigna | 0.333898 |
| antecedentes ganglionares n2b–n3 | 0.348129 |
| nivel v | 0.341116 |
| M0 TX | 0.345233 |
| CA Cancer | 0.341917 |
| squamous epithelium | 0.334337 |
| cirugÃa transoral versus | 0.32767 |
| Cancer Res | 0.419675 |
| clinical implications | 0.349857 |
| DeVita VT Jr | 0.346296 |
| Human papillomavirus infection | 0.357131 |
| VPH tipo | 0.33416 |
| Natl Cancer Inst | 0.562443 |
| enfermedad t4 | 0.338752 |
| nivel ii | 0.349773 |
| neck cancers | 0.968755 |
| human papillomavirus | 0.694615 |
| orofaringe estadio | 0.33767 |
| Head Neck Surg | 0.342719 |
| second primary tumors | 0.391083 |
| Mendenhall WM | 0.327697 |
| Head Neck | 0.399598 |
| estadio iv | 0.354503 |
| M0 T2 | 0.385934 |
|
| M0 T1 | 0.384478 |
| M0 T3 | 0.425033 |
| radioterapia posoperatoria | 0.399508 |
| oral stratified squamous | 0.327772 |
| definiciones tnm | 0.328717 |
| Cancer Staging Manual | 0.397433 |
| múltiples ganglios | 0.776893 |
| cirugÃa versus | 0.380943 |
| Epidemiol Biomarkers Prev | 0.350461 |
| Alto VPH | 0.331071 |
| neck retinoid chemoprevention | 0.329578 |
| oropharyngeal cancers versus | 0.33045 |
| ganglios retrofarÃngeos | 0.460243 |
| Oral Pathol Med | 0.327912 |
| MD Anderson Cancer | 0.350182 |
| index tumor site | 0.345356 |
| field cancerization | 0.375139 |
| ganglios linfáticos retrofarÃngeos | 0.70114 |
| M0 Tis | 0.349862 |
| Braakhuis BJ | 0.34369 |
| oropharyngeal cancer | 0.750404 |
| M0 T4a | 0.419704 |
| neck tumors frequently | 0.331875 |
| AJCC Cancer Staging | 0.401717 |
|
CLICK HERE |
| 1898 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de recto (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de recto. |
| pequeña porción | 0.344303 |
| siguientes procedimientos | 0.488361 |
| estadio iv | 0.798609 |
| siguientes aspectos | 0.39574 |
| ecografÃa transrectal | 0.363875 |
| siguientes tipos | 0.371556 |
| tumor causa obstrucción | 0.365452 |
| rayos x | 0.358514 |
| estadio ivb | 0.576844 |
| enlace drugs approved | 0.373438 |
| menor cantidad | 0.340782 |
| escáner tep | 0.363457 |
| ondas sonoras | 0.360161 |
| estadio iva | 0.572549 |
| información ayuda | 0.344729 |
| recto forma | 0.870609 |
| quimioterapia sistémica | 0.542487 |
| proteÃna llamada factor | 0.366746 |
| National Cancer Institute | 0.340908 |
| recto recidivante | 0.833054 |
|
| cáncer.ampliar colonoscopia | 0.503991 |
| Instituto Nacional | 0.373842 |
| estadio iiia | 0.782206 |
| PDQ Tratamiento | 0.378717 |
| antecedentes familiares | 0.362005 |
| estadio iiic | 0.75767 |
| estadio iiib | 0.767428 |
| estadio iia | 0.790435 |
| siguientes problemas | 0.397252 |
| estadio iic | 0.78747 |
| células cancerosas.El bevacizumab | 0.411094 |
| Physician Data Query | 0.44928 |
| Malestar abdominal | 0.370918 |
| Rectal Cancer | 0.347301 |
| crecer.El ziv-aflibercept | 0.34268 |
| antÃgeno carcinoembrionario | 0.591724 |
| sección cáncer | 0.945618 |
| ano).ampliar extirpación | 0.350725 |
| siguientes sumarios | 0.436031 |
| siguientes pruebas | 0.396087 |
|
CLICK HERE |
| 2041 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de vejiga y otros cánceres uroteliales (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar sistemáticamente el cáncer de vejiga. |
| antecedentes familiares | 0.40081 |
| Schistosoma haematobium | 0.417111 |
| Visuals Online | 0.357081 |
| PDQ Exámenes | 0.503031 |
| Physician Data Query | 0.696072 |
| Estados Unidos | 0.406708 |
| túbulos renales | 0.432914 |
| prevención revisa | 0.368302 |
| sistema urinario masculino | 0.518469 |
|
| largo plazo | 0.406946 |
| vejiga almacena | 0.840919 |
| información ayuda | 0.374743 |
| biopsia.ampliar cistoscopia | 0.431465 |
| National Cancer Institute | 0.400139 |
| siguientes riesgos | 0.364163 |
| pelvis renal | 0.934476 |
| Instituto Nacional | 0.483729 |
|
CLICK HERE |
| 14599 |
National Cancer Institute |
Html |
en |
PET-CT–Guided Surveillance May Reduce Need for Surgery in Some Patients with Advanced Head and Neck Cancer |
Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance had fewer operations but similar overall survival rates to those of patients who underwent planned neck dissection. |
| fewer neck dissections | 0.480753 |
| different PET-imaging systems | 0.416156 |
| trial | 0.383529 |
| surgical dissection | 0.49691 |
| surgery group | 0.546725 |
| equivocal response | 0.373027 |
| main goal | 0.370069 |
| standard first-line therapy | 0.446339 |
| 2-year overall survival | 0.421723 |
| results | 0.372041 |
| PET-CT–guided surveillance | 0.384586 |
| PET-CT group | 0.386097 |
| advanced squamous cell | 0.578344 |
| standardized PET imaging | 0.419169 |
| heterogeneous study population | 0.413368 |
| 2,200-per-patient cost savings | 0.413451 |
| study groups | 0.42202 |
| patients | 0.610711 |
| metabolic abnormalities | 0.37096 |
| Dr. Malik | 0.419332 |
| health care costs | 0.414997 |
| lymph nodes | 0.375275 |
| overall survival rates | 0.55552 |
| surveillance group | 0.491325 |
|
| chemoradiation | 0.396529 |
| Shakun Malik | 0.372291 |
| nodal metastases | 0.375714 |
| positron-emission tomography | 0.373068 |
| magnetic resonance imaging | 0.431542 |
| Cancer Research UK | 0.422638 |
| Technology Assessment Programme | 0.42519 |
| United States | 0.41309 |
| N3 disease | 0.374897 |
| fewer operations | 0.382441 |
| randomized controlled PET-NECK | 0.429823 |
| PET-CT imaging | 0.485125 |
| advanced imaging techniques | 0.434786 |
| neck dissection | 0.819668 |
| PET-CT surveillance | 0.497223 |
| neck dissection patients | 0.544115 |
| Hisham Mehanna | 0.370962 |
| long-term results | 0.369928 |
| trial results | 0.371832 |
| United Kingdom | 0.369679 |
| cancer treatment centers | 0.428263 |
| substantial complications | 0.369604 |
| New England Journal | 0.442645 |
| clinical usefulness | 0.371858 |
|
CLICK HERE |
| 16637 |
National Cancer Institute |
Html |
en |
Metformin: Can a Diabetes Drug Help Prevent Cancer? |
An article about the diabetes drug metformin, which research suggests may help prevent cancer. |
| metformin derivative | 0.623089 |
| cancer treatment | 0.490275 |
| study participants | 0.484909 |
| Dr. Heckman-Stoddard | 0.535865 |
| Family Comprehensive Cancer | 0.513801 |
| metformin arm | 0.64832 |
| early-phase prevention trials | 0.505251 |
| substantially lower risk | 0.487063 |
| original metformin formulation | 0.653789 |
| extensive laboratory research | 0.487291 |
| conventional antidiabetic doses | 0.482196 |
| Phase Prevention Trials | 0.510585 |
| clinical trials | 0.598194 |
| DPP Outcomes Study | 0.570815 |
| early-stage breast cancer | 0.516459 |
| laboratory studies | 0.518492 |
| Cancer Center | 0.508828 |
| Dr. Pollak | 0.522365 |
| triple-negative breast cancer | 0.514736 |
| postmenopausal breast cancer | 0.520249 |
| Dr. Zell | 0.51558 |
| cancer survivors | 0.511148 |
| Diego Moores Cancer | 0.510708 |
| metformin treatment | 0.637604 |
| large epidemiologic studies | 0.500626 |
|
| breast cancer cells | 0.511965 |
| cancer prevention | 0.554231 |
| primary cancer | 0.48954 |
| certain blood biomarkers | 0.485052 |
| cancer outcomes | 0.485417 |
| metformin derivatives | 0.623142 |
| blood biomarkers | 0.487459 |
| smaller prevention trials | 0.498934 |
| metformin | 0.934872 |
| breast cancer | 0.751317 |
| metformin’s effect | 0.638135 |
| cancer development | 0.510096 |
| early-stage clinical trials | 0.564264 |
| metformin’s impact | 0.702491 |
| breast cancer recurrences | 0.517045 |
| cancer clinical trials | 0.527071 |
| Diabetes Prevention Program | 0.513336 |
| cancer risk | 0.512957 |
| early-phase clinical trial | 0.492505 |
| cancer | 0.791776 |
| prevention trials | 0.556708 |
| diabetes drug metformin | 0.743736 |
| cancer incidence | 0.513399 |
| Antonio Breast Cancer | 0.515009 |
|
CLICK HERE |
| 16852 |
National Cancer Institute |
Html |
en |
University of California, San Diego — Cancer Research in Nanotechnology (CRIN) |
Provides trainees with a balanced combination comprehensive cancer biology, engineering, and entrepreneurship didactic training, including cancer researcher, clinical/translational cancer faculty, and practical skills in small business environments. |
| synergy | 0.439136 |
| dearth | 0.464725 |
| promise | 0.439416 |
| issues | 0.469099 |
| oral presentations | 0.597869 |
| investigators | 0.43726 |
| San Diego | 0.64989 |
| spite | 0.453494 |
| academia | 0.440105 |
| research advances | 0.635659 |
| academic mentors | 0.611308 |
| Ph.D. | 0.437454 |
| nanotechnology | 0.493685 |
| medical device | 0.611406 |
| cancer therapies | 0.658537 |
| California | 0.440505 |
| engineering/materials science | 0.617993 |
| University | 0.440535 |
| success | 0.436075 |
| comprehensive set | 0.611033 |
| training program | 0.629484 |
| clinical/translational cancer faculty | 0.809173 |
| Current PhD | 0.611308 |
| comprehensive cancer biology | 0.812096 |
| trainees | 0.625803 |
|
| cross training | 0.614905 |
| postdoctoral training | 0.632853 |
| CRIN | 0.480296 |
| cancer research | 0.980901 |
| science cancer researcher | 0.808302 |
| present research proposals | 0.781791 |
| laboratory experience | 0.604598 |
| practical skills | 0.600189 |
| National Cancer Institute | 0.811595 |
| Principal Investigator | 0.635275 |
| young scientists | 0.755823 |
| small firm | 0.611549 |
| cancer. | 0.433521 |
| Dong-Er Zhang | 0.641012 |
| entrepreneurship didactic training | 0.808298 |
| academia. | 0.434053 |
| life. Engineering approaches | 0.803444 |
| Andrew Kummel | 0.630977 |
| application | 0.436257 |
| discoveries | 0.437754 |
| device companies | 0.613133 |
| cancer biology | 0.906785 |
| small business entrepreneurs | 0.772007 |
| academic career path | 0.764024 |
|
CLICK HERE |
| 17292 |
National Cancer Institute |
Html |
es |
Sangrado y moretones (trombocitopenia) |
Información y consejos para controlar el sangrado y los moretones, los cuales son efectos secundarios del tratamiento del cáncer. |
|
|
CLICK HERE |